Video Experimental Relacionado
Updated: May 12, 2026
08:27
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
14.9K
Efectos de la lactilación en las características del cáncer (Revisión)
Yujie Fan1, Zhangda Chen1, Jiaxin Li1
1Department of General Surgery, Wenzhou Medical University Lishui Hospital and Lishui City People's Hospital, Lishui, Zhejiang 323000, P.R. China.
Oncology letters
|September 3, 2025
Resumen
La lactilación, una modificación metabólica, vincula el cáncer
Área de la Ciencia:
- La bioquímica
- Biología del cáncer
- La epigenética
Sus antecedentes:
- La lactilación es una modificación post-traduccional emergente.
- Enlaza la reprogramación metabólica y la regulación epigenética en el cáncer.
Objetivo del estudio:
- Para revisar cómo la lactilación conduce las señales de cáncer.
- Para explorar su papel en el microambiente tumoral (EMT).
- Para resaltar las estrategias terapéuticas dirigidas a la lactilación.
Principales métodos:
- Revisión sistemática de la literatura existente.
- Análisis de las funciones reguladoras de la lactilación en las proteínas histónicas y no histónicas.
- Examen del impacto de la lactilación en las características del cáncer y la EMT.
Principales resultados:
- La lactilación regula las características clásicas y emergentes del cáncer.
- Da forma a una EMT inmunosupresora y promueve la resistencia al tratamiento.
- La lactilación influye en la reprogramación metabólica, el escape inmune y los cambios epigenéticos.
Conclusiones:
- La lactilación es un factor clave de la progresión del cáncer y la resistencia terapéutica.
- La orientación de las vías de lactilación ofrece nuevas estrategias anticancerígenas de precisión.
- La interrupción del cruce metabólico-epigenético a través de la modulación de la lactilación es una vía terapéutica prometedora.
Videos de Conceptos Relacionados
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...